Oxidative Stress: A common denominator in the pathogenesis of amyotrophic lateral sclerosis

Current Opinion in Rheumatology

Volumn 15, Issue 6, 2003, Pages 730-736

  Simpson, Ericka P ^a   Yen, Albert A ^a   Appel, Stanley H ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

Amyotrophic lateral sclerosis; Excitotoxicity; Immune activation; Oxidative stress

Indexed keywords

AMINO ACID TRANSPORTER; AMPA RECEPTOR; AMPA RECEPTOR AGONIST; BETA2 INTEGRIN; BIOLOGICAL MARKER; COPPER ZINC SUPEROXIDE DISMUTASE; EPIDERMAL GROWTH FACTOR; GENE PRODUCT; GLUTAMATE RECEPTOR; GLUTAMIC ACID; PROTEIN SUBUNIT; REACTIVE OXYGEN METABOLITE;

AMYOTROPHIC LATERAL SCLEROSIS; APOPTOSIS; CELL DEATH; CELL LOSS; CHROMOSOME 21; CLINICAL FEATURE; DEGENERATIVE DISEASE; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE PREDISPOSITION; EPIDEMIOLOGICAL DATA; FAMILIAL DISEASE; GENE LOCUS; GENE MUTATION; HUMAN; IMMUNITY; MAJOR HISTOCOMPATIBILITY COMPLEX; MOTONEURON; MOTOR CORTEX; MOTOR NEURON DISEASE; NERVE CELL DEGENERATION; NEUROTOXICITY; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; SPINAL CORD; THEORY;

AMYOTROPHIC LATERAL SCLEROSIS; ANTIOXIDANTS; FEMALE; HUMANS; MALE; OXIDATION-REDUCTION; OXIDATIVE STRESS; PROGNOSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 0742321930     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-200311000-00008     Document Type: Review

References (81)

1. Magnus T, Beck M, Giess R, et al.: Disease progression in amyotrophic lateral sclerosis: predictors of survival. Muscle Nerve 2002, 25:709-714.
2. Iwasaki Y, Ikeda K, Ichikawa Y, et al.: The diagnostic interval in amyotrophic lateral sclerosis. Clin Neurol Neurosurg 2002, 104:87-89. Bulbar onset ALS is more frequent in the older female population and shortens the interval between symptom onset and diagnosis.
3. Haverkamp LJ, Appel V, Appel SH: Natural history of amyotrophic lateral sclerosis in a database population: validation of a scoring system and a model for survival prediction. Brain 1995, 118:707-719.
4. Sorenson EJ, Stalker AP, Kurland LT, et al.: Amyotrophic lateral sclerosis in Olmsted County, Minnesota, 1925 to 1998. Neurology 2002, 59:280-282. Prospective study of incidence of ALS over a period of 70 years in a single community, showing the stability of ALS case incidence, survival time, and time to diagnosis over time.
5. Annegers JF, Appel S, Lee JR, et al.: Incidence and prevalence of amyotrophic lateral sclerosis in Harris County, Texas, 1985-88. Arch Neurol 1991, 48:589-593.
6. Traynor BJ, Codd MB, Corr B, et al.: Incidence and prevalence of ALS in Ireland, 1995-97: a population-based study. Neurology 1999, 52:504-509.
7. Rudnicki SA: Estrogen replacement therapy in women with amyotrophic lateral sclerosis. J Neurol Sci 1999, 169:126-127.
8. Mandrioli J, Faglioni P, Merelli E, et al.: The epidemiology of ALS in Modena, Italy. Neurology 2003, 60:683-689.
9. Rogers M, Evans W: Changes in skeletal muscle with aging: effects of exercise training. Exerc Sport Sci Rev 1993, 21:65-102.
10. Tomlinson B, Irving D: The numbers of limb motor neurons in the human lumbosacral cord throughout life. J Neurol Sci 1977, 35:213-219.
11. Siddique T, Figlewicz DA, Pericak-Vance MA, et al.: Linkage of a gene causing familial amyotrophic lateral sclerosis to chromosome 21 and evidence of genetic-locus heterogeneity. N Engl J Med 1991, 324:1381-1384.
12. Rosen DR, Siddique T, Patterson D, et al.: Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993, 362:59-62.
13. Corcia P, Mayeux-Portas V, Khoris J, et al.: Abnormal SMN1 gene copy number is a susceptibility factor for amyotrophic lateral sclerosis. Ann Neurol 2002, 51:243-246. A study documenting increased percentage of patients with ALS with an abnormal copy for survival motor neuron 1 gene compared with controls.
14. Lacomblez L, Doppler V, Beucler I, et al.: APOE: a potential marker of disease progression in ALS. Neurology 2002, 58:1112-1114. Apolipoprotein E (APOE) lipoprotein plasma levels are significantly elevated in patients with ALS and correlate with poorer survival and faster rate of progression.
15. Andersen PM: Genetics of sporadic ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 2001, 2(suppl 1):S37-S41.
16. Al-Chalabi A, Andersen PM, Nilsson P, et al.: Deletions of the heavy neuro-filament subunit tail in amyotrophic lateral sclerosis. Hum Mol Genet 1999, 8:157-164.
17. Comi GP, Bordoni A, Salani S, et al.: Cytochrome c oxidase subunit I microdeletion in a patient with motor neuron disease. Ann Neurol 1998, 43:110-116.
18. Hayward C, Colville S, Swingler RJ, et al.: Molecular genetic analysis of the APEX nuclease gene in amyotrophic lateral sclerosis. Neurology 1999, 52:1899-1901.
19. Singh P, Mann KA, Mangat HK, et al.: Prolonged glutamate excitotoxicity: effects on mitochondrial antioxidants and antioxidant enzymes. Mol Cell Biochem 2003, 243:139-145. This is a recent study of glutamate excitotoxicity in Wistar rat brains mediated by mitochondrial impairment and increased lipid peroxidation.
20. Rao SD, Yin HZ, Weiss JH: Disruption of glial glutamate transport by reactive oxygen species produced in motor neurons. J Neurosci 2003, 23:2627-2633. This article emphasizes the importance of interactions between motor neurons and glia.
21. Koutsilieri E, Scheller C, Tribl F, et al.: Degeneration of neuronal cells due to oxidative stress-microglial contribution. Parkinsonism Relat Disord 2002, 8:401-406. This article discusses the role of oxidative stress in neurodegeneration and the intracellular signals involved in activating pathways leading to neuronal injury. Microglia are discussed as sources of oxidative stress.
22. Cutler RG, Pedersen WA, Camandola S, et al.: Evidence that accumulation of ceramides and cholesterol esters mediates oxidative stress-induced death of motor neurons in amyotrophic lateral sclerosis. Ann Neurol 2002, 52:448-457. This article documents a specific pathway, involving abnormal sphingolipid metabolism, by which oxidative stress causes motor neuron death.
23. Rakhit R, Cunningham P, Furtos-Matei A, et al.: Oxidation-induced misfolding and aggregation of superoxide dismutase and its implications for amyotrophic lateral sclerosis. J Biol Chem 2002, 277:47551-47556. This study links oxidative stress with protein misfolding and aggregation.
24. Dal Canto MC, Gurney ME: Neuropathological changes in two lines of mice carrying a transgene for mutant human Cu,Zn SOD, and in mice overexpressing wild type human SOD: a model of familial amyotrophic lateral sclerosis (FALS). Brain Res 1995, 676:25-40.
25. Dal Canto MC, Gurney ME: Development of central nervous system pathology in a murine transgenic model of human amyotrophic lateral sclerosis. Am J Pathol 1994, 145:1271-1279.
26. Lino MM, Schneider C, Caroni P: Accumulation of SOD1 mutants in postnatal motoneurons does not cause motoneuron pathology or motoneuron disease. J Neurosci 2002, 22:4825-4832. Mutant SOD1 gene restricted expression in mouse motor neurons does not cause disease, implicating nonneuronal cells in the disease.
27. Pramatarova A, Laganiere J, Roussel J, et al.: Neuron-specific expression of mutant superoxide dismutase 1 in transgenic mice does not lead to motor impairment. J Neurosci 2001, 21:3369-3374.
28. Gong YH, Parsadanian AS, Andreeva A, et al.: Restricted expression of G86R Cu/Zn superoxide dismutase in astrocytes results in astrocytosis but does not cause motoneuron degeneration. J Neurosci 2000, 20:660-665.
29. Gu Z, Kaul M, Yan B, et al.: S-nitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death. Science 2002, 297:1186-1190.
30. Lu C, Chan SL, Haughey N, et al.: Selective and biphasic effect of the membrane lipid peroxidation product 4-hydroxy-2,3-nonenal on N-methyl-D-aspartate channels. J Neurochem 2001, 78:577-589.
31. Picklo MJ, Amarnath V, McIntyre JO, et al.: 4-Hydroxy-2(E)-nonenal inhibits CNS mitochondrial respiration at multiple sites. J Neurochem 1999, 72:1617-1624.
32. Pedersen WA, Cashman NR, Mattson MP: The lipid peroxidation product 4-hydroxynonenal impairs glutamate and glucose transport and choline acetyltransferase activity in NSC-19 motor neuron cells. Exp Neurol 1999, 155:1-10.
33. Shringarpure R, Grune T, Sitte N, et al.: 4-Hydroxynonenal-modified amyloid-beta peptide inhibits the proteasome: possible importance in Alzheimer's disease. Cell Mol Life Sci 2000, 57:1802-1809.
34. Bowling AC, Schulz JB, Brown RH Jr, et al.: Superoxide dismutase activity, oxidative damage, and mitochondrial energy metabolism in familial and sporadic amyotrophic lateral sclerosis. J Neurochem 1993, 61:2322-2325.
35. Shibata N, Nagai R, Uchida K, et al.: Morphological evidence for lipid peroxidation and protein glycoxidation in spinal cords from sporadic amyotrophic lateral sclerosis patients. Brain Res 2001, 917:97-104.
36. Ferrante RJ, Browne SE, Shinobu LA, et al.: Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. J Neurochem 1997, 69:2064-2074,
37. Pedersen WA, Fu W, Keller JN, et al.: Protein modification by the lipid peroxidation product 4-hydroxynonenal in the spinal cords of amyotrophic lateral sclerosis patients. Ann Neurol 1998, 44:819-824.
38. Oteiza PI, Uchitel OD, Carrasquedo F, et al.: Evaluation of antioxidants, protein, and lipid oxidation products in blood from sporadic amyotrophic lateral sclerosis patients. Neurochem Res 1997, 22:535-539.
39. Bogdanov M, Brown RH, Matson W, et al.: Increased oxidative damage to DNA in ALS patients. Free Radic Biol Med 2000, 29:652-658.
40. Andrus PK, Fleck TJ, Gurney ME, et al.: Protein oxidative damage in a transgenic mouse model of familial amyotrophic lateral sclerosis. J Neurochem 1998, 71:2041-2048.
41. Nagano S, Fujii Y, Yamamoto T, et al.: The efficacy of trientine or ascorbate alone compared to that of the combined treatment with these two agents in familial amyotrophic lateral sclerosis model mice. Exp Neurol 2003, 179:176-180. Specific therapy targeted to pro-oxidant effect of mutant SOD1 toxicity prolonged survival in transgenic mouse only when started before disease.
42. Wu AS, Kiaei M, Aguirre N, et al.: Iron porphyrin treatment extends survival in a transgenic animal model of amyotrophic lateral sclerosis. J Neurochem 2003, 85:142-150. Broad range antioxidant therapy is beneficial in the mutant SOD1 transgenic mouse.
43. Desnuelle C, Dib M, Garrel C, et al.: A double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS Riluzole-Tocopherol Study Group. Amyotroph Lateral Scler Other Motor Neuron Disord 2001, 2:9-18.
44. Lange DJ, Murphy PL, Diamond B, et al.: Selegiline is ineffective in a collaborative double-blind, placebo-controlled trial for treatment of amyotrophic lateral sclerosis. Arch Neurol 1998, 55:93-96.
45. Vyth A, Timmer JG, Bossuyt PM, et al.: Survival in patients with amyotrophic lateral sclerosis, treated with an array of antioxidants. J Neurol Sci 1996, 139(suppl):99-103.
46. Headley PM, Grillner S: Excitatory amino acids and synaptic transmission: the evidence for a physiological function. Trends Pharmacol Sci 1990, 11:205-211.
47. Mattson MP, Mark RJ: Excitotoxicity and excitoprotection in vitro. Adv Neurol 1996, 71:1-37.
48. Rothstein JD, Jin L, Dykes-Hoberg M, et al.: Chronic inhibition of glutamate uptake produces a model of slow neurotoxicity. Proc Natl Acad Sci U S A 1993, 90:6591-6595.
49. Vandenberghe W, Robberecht W, Brorson JR: AMPA receptor calcium permeability, GluR2 expression, and selective motoneuron vulnerability. J Neurosci 2000, 20:123-132.
50. Nakamura R, Kamakura K, Kwak S: Late-onset selective neuronal damage in the rat spinal cord induced by continuous intrathecal administration of AMPA. Brain Res 1994, 654:279-285.
51. Cid C, Alvarez-Cermeno JC, Regidor I, et al.: Low concentrations of glutamate induce apoptosis in cultured neurons: implications for amyotrophic lateral sclerosis. J Neurol Sci 2003, 206:91-95. This article provides in vitro evidence that AMPA receptors can mediate glutamate neurotoxicity.
52. Heath PR, Shaw PJ: Update on the glutamatergic neurotransmitter system and the role of excitotoxicity in amyotrophic lateral sclerosis. Muscle Nerve 2002, 26:438-458.
53. Kawahara Y, Kwak S, Sun H, et al.: Human spinal motoneurons express low relative abundance of GluR2 mRNA: an implication for excitotoxicity in ALS. J Neurochem 2003, 85:680-689. Quantitative reverse-transcription polymerase chain reaction and laser microdissection techniques are used to examine AMPR receptor subunit mRNA levels in different neuronal subsets and tissues.
54. Takuma H, Kwak S, Yoshizawa T, et al.: Reduction of GluR2 RNA editing, a molecular change that increases calcium influx through AMPA receptors, selective in the spinal ventral gray of patients with amyotrophic lateral sclerosis. Ann Neurol 1999, 46:806-815.
55. Rothstein JD, Van Kammen M, Levey AI, et al.: Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol 1995, 38:73-84.
56. Canton T, Pratt J, Stutzmann J-M, et al.: Glutamate uptake is decreased tardively in the spinal cord of FALS mice. Neuroreport 1998, 9:775-778.
57. Trotti D, Danbolt NC, Volterra A: Glutamate transporters are oxidant-vulnerable: a molecular link between oxidative and excitotoxic neurodegeneration? Trends Pharmacol Sci 1998, 19:328-334.
58. Dunlop J, Mcllvain HB, She Y, et al.: Impaired spinal cord glutamate transport capacity and reduced sensitivity to riluzole in a transgenic superoxide dismutase mutant rat model of amyotrophic lateral sclerosis. J Neurosci 2003, 23:1688-1696. Glutamate transport function is studied at different stages of disease in the G93A mSOD1 rat model.
59. Su Z, Leszczyniecka M, Kang D, et al.: Insights into glutamate transport regulation in human astrocytes: cloning of the promoter for excitatory amino acid transporter 2 (EAAT2). Proc Natl Acad Sci USA 2003, 100:1955-1960. This article describes the cloning and characterization of the human EAAT2 promoter. Regulators of EAAT2 transport are also detailed.
60. McGeer PL, Itagaki S, McGeer EG: Expression of the histocompatibility glycoprotein HLA-DR in neurological disease. Acta Neuropathol (Berl) 1988, 76:550-557.
61. Kawamata T, Akiyama H, Yamada T, et al.: Immunologic reactions in amyotrophic lateral sclerosis brain and spinal cord tissue. Am J Pathol 1992, 140:691-707.
62. Troost D, Van den Oord JJ, Vianney de Jong JM: Immunohistochemical characterization of the inflammatory infiltrate in amyotrophic lateral sclerosis. Neuropathol Appl Neurobiol 1990, 16:401-410.
63. Almer G, Teismann P, Stevic Z, et al.: Increased levels of the pro-inflammatory prostaglandin PGE2 in CSF from ALS patients. Neurology 2002, 58:1277-1279.
64. Liu B, Gao HM, Wang JY, et al.: Role of nitric oxide in inflammation-mediated neurodegeneration. Ann N Y Acad Sci 2002, 962:318-331.
65. Bal-Price A, Brown GC: Inflammatory neurodegeneration mediated by nitric oxide from activated glia-inhibiting neuronal respiration, causing glutamate release and excitotoxicity. J Neurosci 2001, 21:6480-6491.
66. Le W, Rowe D, Xie W, et al.: Microglial activation and dopaminergic cell injury: an in vitro model relevant to Parkinson's disease. J Neurosci 2001, 21:8447-8455.
67. Almer G, Guegan C, Teismann P, et al.: Increased expression of the proinflammatory enzyme cyclooxygenase-2 in amyotrophic lateral sclerosis. Ann Neurol 2001, 49:176-185.
68. Yasojima K, Tourtellotte WW, McGeer EG, et al.: Marked increase in cyclooxygenase-2 in ALS spinal cord: implications for therapy. Neurology 2001, 57:952-956.
69. Nakamura Y, Ohmaki M, Murakami K, et al.: Involvement of protein kinase C in glutamate release from cultured microglia. Brain Res 2003, 962:122-128. Activated microglia-associated toxicity is mediated by glutamate and nitric oxide release through pathways involving protein kinase C. These pathways may be amenable to therapy targeted to these pathways.
70. Lee YB, Nagai A, Kim SU: Cytokines, chemokines, and cytokine receptors in human microglia. J Neurosci Res 2002, 69:94-103.
71. Stolzing A, Wengner A, Grune T: Degradation of oxidized extracellular proteins by microglia. Arch Biochem Biophys 2002, 400:171-179. This study describes the mechanism by which microglia degrade oxidized proteins and the potential for chronic microglial activation and toxicity in response to significantly oxidized proteins.
72. Keller JN, Hanni KB, Gabbita SP, et al.: Oxidized lipoproteins increase reactive oxygen species formation in microglia and astrocyte cell lines. Brain Res 1999, 830:10-15.
73. Keller JN, Hanni KB, Markesbery WR: Oxidized low-density lipoprotein induces neuronal death: implications for calcium, reactive oxygen species, and caspases. J Neurochem 1999, 72:2601-2609.
74. Glabinski AR, Balasingam V, Tani M, et al.: Chemokine monocyte chemoattractant protein-1 is expressed by astrocytes after mechanical injury to the brain. J Immunol 1996, 156:4363-4368.
75. McTigue DM, Tani M, Krivacic K, et al.: Selective chemokine mRNA accumulation in the rat spinal cord after contusion injury. J Neurosci Res 1998, 53:368-376.
76. Shaw PJ, Eggett CJ: Molecular factors underlying selective vulnerability of motor neurons to neurodegeneration in amyotrophic lateral sclerosis. J Neurol 2000, 247(suppl 1):I17-I27.
77. Pamphlett R: Detection and cellular localization of enterovirus RNA sequences in spinal cord of patients with ALS. Neurology 2000, 55:1420-1421.
78. Brooks BR: Risk factors in the early diagnosis of ALS: North American epidemiological studies. ALS CARE Study Group. Amyotroph Lateral Scler Other Motor Neuron Disord 2000, 1 (suppl 1):S19-S26.
79. Nelson LM, McGuire V, Longstreth WT Jr, et al.: Population-based case-control study of amyotrophic lateral sclerosis in western Washington State, I: cigarette smoking and alcohol consumption. Am J Epidemiol 2000, 151:156-163.
80. Perry G, Sayre LM, Atwood CS, et al.: The role of iron and copper in the aetiology of neurodegenerative disorders: therapeutic implications. CNS Drugs 2002, 16:339-352. This article reviews the role of metals in neurodegeneration as initiators of oxidative stress.
81. Jackson M, Steers G, Leigh PN, et al.: Polymorphisms in the glutamate transporter gene EAAT2 in European ALS patients. J Neurol 1999, 246:1140-1144.